

IN THE CLAIMS:

Claims 1-42 (Cancelled)

Claim 43 (New) A process for the production of biologically active VEGF-B, said method comprising expressing a nucleic acid molecule which hybridizes under high stringency conditions to a full-length reverse complement of a nucleic acid of SEQ ID NOS: 3, 5, 7 and 9 in a host and isolating said VEGF-B, wherein said high stringency conditions comprise 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

Claim 44 (New) A process for the production of biologically active VEGF-B, said method comprising expressing a nucleic acid molecule which hybridizes under high stringency conditions to a full-length reverse complement of a nucleic acid of SEQ ID NO:3 in a host and isolating said VEGF-B, wherein said high stringency conditions comprise 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

Claim 45 (New) A process for the production of biologically active VEGF-B, said method comprising expressing a nucleic acid molecule which hybridizes under high stringency conditions to a full-length reverse complement of a nucleic acid of SEQ ID NO:5 in a host and isolating said VEGF-B, wherein said high stringency conditions comprise 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

Claim 46 (New) A process for the production of biologically active VEGF-B, said method comprising expressing a nucleic acid molecule which hybridizes under high stringency conditions to a full-length reverse complement of a nucleic acid of SEQ ID NO:7 in a host and isolating said VEGF-B, wherein said high stringency conditions comprise 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

Claim 47 (New) A process for the production of biologically active VEGF-B, said method comprising expressing a nucleic acid molecule which hybridizes under high stringency conditions to a full-length reverse complement of a nucleic acid of SEQ ID NO:9 in a host and isolating said VEGF-B, wherein said high stringency conditions comprise 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

Claim 48 (New) The process according to any one of Claims 43-48 wherein said VEGF-B is human VEGF-B.